melanoma
Current clinical investigations have shown great promise with the combination of trametinib and dabrafenib in patients with BRAF-mutant melanoma; a number of clinical trials of trametinib in combination with other targeted drugs are underway.
Current clinical investigations have shown great promise with the combination of trametinib and dabrafenib in patients with <span class="gene" id="23432625-9-124-128">BRAF</span>-mutant <span class="disease" id="23432625-9-136-144">melanoma</span>; a number of clinical trials of trametinib in combination with other targeted drugs are underway.